Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

CALGARY and CLEVELAND, Oct. 22, 2015 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX), a phase 3 clinical-stage epigenetics company, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25^th to October 28^th at The Cleveland Clinic in Cleveland, Ohio. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.  A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The current Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.

Michael Moffat, Cavendish co-founder and chief executive officer explains, "The theme of our Cleveland Clinic hosted Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.'  With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence.  The quality and originality of Resverlogix Corp.'s research and scientific insights into epigenetic drug discovery positions them to make a major contribution to the treatment of cardiovascular and autoimmune diseases."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to cardiovascular disease and the treatment of the number one killer of both men and women around the world today," said Donald McCaffrey, president and chief executive officer. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over $260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations which they are passionate about with other family offices from around the world.

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations. For more information: http://cavendishglobal.com

About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining an excellent safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Resverlogix's Phase 3 clinical trial BETonMACE in high-risk CVD patients with DM and low HDL is planned to commence in the fall of 2015. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.

For further information, please contact:

Alex Charlton
President, Cavendish Global
Email: [email protected]  
Tel: +1-917-576-1435
 
Donald J. McCaffrey 
President and CEO, Resverlogix Corp.
Email: [email protected]
Tel: 403-254-9252

SOURCE Resverlogix Corp.

Related Links

http://www.resverlogix.com